Neuroprotective therapy in advanced primary open-angle glaucoma

Dorofeev D.A.; Kozlova I.V.; Vereshchagina A.I.

doi:https://doi.org/10.17116/oftalma202514106175

Dorofeev D.A.

Krasnov Research Institute of Eye Diseases;
City Glaucoma Center at the City Clinical Hospital No. 2, Chelyabinsk Polyclinic No. 1

Kozlova I.V.

Krasnov Research Institute of Eye Diseases

ORCID: 0000-0003-3885-9649

Vereshchagina A.I.

Pirogov Russian National Research Medical University

ORCID: 0009-0000-3704-2886

Neuroprotective therapy in advanced primary open-angle glaucoma

Authors:

Dorofeev D.A., Kozlova I.V., Vereshchagina A.I.

More about the authors

Journal: Russian Annals of Ophthalmology. 2025;141(6): 75‑80

DOI: 10.17116/oftalma202514106175

Read: 383 times

Contact the author

Table of contents

To cite this article:

Dorofeev DA, Kozlova IV, Vereshchagina AI. Neuroprotective therapy in advanced primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;141(6):75‑80. (In Russ.)
https://doi.org/10.17116/oftalma202514106175

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)

Использование инфографики авторами научных работ

PURPOSE

This study aimed to assess the changes in structural and functional characteristics of the visual analyzer in patients with advanced primary open-angle glaucoma (POAG) in the course of long-term regular use of Retinalamin (Geropharm, Russia).

MATERIAL AND METHODS

The study was conducted from 2022 to 2024 at two clinical centers: the M.M. Krasnov Research Institute of Eye Diseases and the Chelyabinsk Glaucoma Center. This multicenter cohort prospective study examined the structural and functional parameters of the visual analyzer in patients with advanced POAG during long-term regular use of Retinalamin.

The study included a total of 56 patients (98 eyes) divided into two groups. The observation group comprised patients with advanced glaucoma who regularly received 10 intramuscular injections of Retinalamin 5 mg (Geropharm, Russia) diluted in 1.0 mL of 0.9% sodium chloride solution in outpatient setting once every three months over a two-year period. The control group consisted of patients with advanced glaucoma who did not receive neuroprotective therapy.

RESULTS

At baseline, all patients in both groups had achieved target intraocular pressure (IOP) through surgical and/or medical treatment, which remained stable throughout the follow-up period.

The mean deviation (MD) decreased by 0.98 (0.78; 1.76) dB/year in the observation group and by 1.65 (0.59; 1.79) dB/year in the control group. The pattern standard deviation (PSD) increased by 0.02 (–0.3; 1.2) dB/year in the observation group and by 0.3 (0.7; 1.3) dB/year in the control group. Mean retinal nerve fiber layer (RNFL) thickness showed a similar trend. Following repeated courses of Retinalamin therapy, the observation group demonstrated stable, minimal decrease in RNFL thickness amounting to 1.5 (–0.25; 5.0) μm/year. The control group exhibited more pronounced decrease in RNFL thickness averaging 3.0 (0.75; 10.2) μm/year.

CONCLUSION

Long-term neuroretinoprotective therapy with Retinalamin (Geropharm, Russia) in patients with advanced POAG is justified when administered regularly and the intraocular pressure is stable and well controlled.

Keywords:

glaucoma

retinal protection

retinalamin

Authors:

Dorofeev D.A.

Krasnov Research Institute of Eye Diseases;
City Glaucoma Center at the City Clinical Hospital No. 2, Chelyabinsk Polyclinic No. 1

Kozlova I.V.

Krasnov Research Institute of Eye Diseases

ORCID: 0000-0003-3885-9649

Vereshchagina A.I.

Pirogov Russian National Research Medical University

ORCID: 0009-0000-3704-2886

Received:

23.10.2025

Accepted:

03.11.2025

Close metadata

References:

Erichev VP, Antonov AA, Kozlova IV. Objective criteria of neuroprotective glaucoma treatment efficacy. National Journal glaucoma. 2018;17(3):50-57. (In Russ.). https://doi.org/10.25700/NJG.2018.03.06
Lovpache DN, Zavadski PCh, Zvereva OG, Kuroyedov AV, Dorofeev DA. et al. Compliance and persistence in patients with primary open-angle glaucoma through the doctor opinions. National Journal glaucoma. 2020;19(2): 11-21. (In Russ.). https://doi.org/10.25700/NJG.2020.02.02
Avdeev RV, Alexandrov AS, Basinsky AS, Blyum EA, Brezhnev AYu et al. Evaluation of clinical and instrumental data of eyes examination in patients with primary open-angle glaucoma and macular degeneration. Bashkortostan Medical Journal. 2014;9(2):24-28.
Avetisov SE, Erichev VP, Fedorov AA, Yaremenko TV, Murakhovskaya YuK. Evaluation of therapeutic sensitivity of retinal ganglion cells to targeted peptide bioregulator in culture. Russian Annals of Ophthalmology= Vestnik oftal’mologii. 2019;135(1):84-89. (In Russ.). https://doi.org/10.17116/oftalma201913501184
Petrov SYu, Subbot AM, Gabashvili AN, Volzhanin AV, Vitkov AA. Rat models of glaucomatous optic neuropathy. National Journal glaucoma. 2017;16(4):79-85. (In Russ.)
Erichev VP, Makarova AS. Compatibility of systemic drugs and local antihypertensive therapy in patients with primary open-angle glaucoma (analytical review). National Journal glaucoma. 2019;18(2):93-101. (In Russ.). https://doi.org/10.25700/NJG.2019.02.10
Antonov AA, Kozlova IV, Vitkov AA, Agadzhanyan TM. A new algorithm of treatment choice in primary open-angle glaucoma. Russian Ophthalmological Journal. 2021;14(4):7-17. (In Russ.). https://doi.org/10.21516/2072-0076-2021-14-4-7-17
Petrov SYu, Aslamazova AE, Reshchikova VS. Prospects for the practical application of biochemical studies in ophthalmology. Clinical ophthalmology. 2015;15(1):41-45. https://doi.org/10.1155/2012/319728.43
Ermolaev AP, Erichev VP, Grigoryan GL, Antonov AA, Kotlyar K, Mazurova YuV, Levitsky YuV, Khderi Kh. Perimetry in patients with limited mobility and bedridden patients using a portable perimeter based on a virtual reality helmet. Glaucoma News. 2019; 1(49):56-57.
Ermolaev AP, Erichev VP, Hderi H, Poleva RP. Clarification of indications for laser iridectomy in the eyes with a predisposition to primary angle-closure glaucoma. POINT OF VIEW EAST — WEST. 2019;(2):19-21. (In Russ.). https://doi.org/10.25276/2410-1257-2019-2-19-21
Egorov EA, Kuroedov AV. Selected clinical and epidemiological characteristics of glaucoma in the CIS countries and Georgia. Results of a multicenter open retrospective study (part 2). RMJ Clinical Ophthalmology. 2012;13(1): 13-22. (In Russ.).
Petrov SYu, Makarova AS, Volzhanin AV. Efficacy and safety profile of generic IOP-lowering agents. National Journal glaucoma. 2017;16(2):27-36. (In Russ.).
Antonov AA, Vitkov AA, Agadzhanyan TM. The efficacy and safety of the domestic travoprost generic in various modes of therapy for primary open-angle glaucoma. National Journal glaucoma. 2021;20(4):50-56. (In Russ.). https://doi.org/10.53432/2078-4104-2021-20-4-50-56
Vitkov AA, Hadiri Kh, Aghajanyan TM. et al. The choice of IOP measurement method for assessing the effectiveness of glaucoma surgery. Natsional’nyi zhurnal glaukoma. 2023; 22(2):39-43. (In Russ.). https://doi.org/10.53432/2078-4104-2023-22-2-39-43
Antonov A.A., Agadzhanyan T.M., Vitkov A.A. Hypotensive efficacy of bimatoprost in the treatment of primary open-angle glaucoma. Natsional’nyi zhurnal glaukoma. 2019; 18(1):95-104. (In Russ.).
Erichev VP, Antonov AA, Vitkov AA, Grigoryan LA. Static automated perimetry in the diagnosis of glaucoma. Part 2: Research protocol, glaucoma classifications, perimetric defects through the prism of structural-functional correlation. Russian Annals of Ophthalmology= Vestnik oftal’mologii. 2021; 137(5-2):289-299. (In Russ.). https://doi.org/10.17116/oftalma2021137052289
Antonov AA, Vitkov AA, Makarova AS, Poleva RP, Vitkova II. Influence of perioperative therapy on filtration bleb formation and ophthalmotonus level after glaucoma surgery. The EYE GLAZ. 2024;26(4):256-263. (In Russ.). https://doi.org/10.33791/2222-4408-2024-4-256-263
Klinicheskie rekomendacii — Glaukoma pervichnaja otkrytougol’naja — 2024 (01.01.2025) — Utverzhdeny Minister. stvom zdravoohranenija Rossijskoj Federacii [Clinical guidelines — Primary open-angle glaucoma — 2024 (01.01.2025) — Approved by the Ministry of Health of the Russian Federation] (In Russ.). https://demo.consultant.ru/cgi/online.cgi?req=doc&base=LAW&n=483971&dst=100207#BOezLwUq2rGRdhA51
Petrov SYu, Antonov AA, Makarova AS, Vostrukhin SV. Intraocular pressure in the assessment of medical and surgical treatment of glaucoma. RMJ. Clinical ophthalomology. 2015; 15(2):69-72. (In Russ.)
Erichev VP, Onishchenko AL, Kuroyedov A V, Petrov SY, Brezhnev AY, Antonov AA, Vitkov AA, Murakhovskaya YK. Ophthalmic risk factors for primary open angle glaucoma. Russian Journal of Clinical Ophthalmology. 2019;19(2):81-86. (In Russ.). https://doi.org/10.32364/2311-7729-2019-19-2-81-86
Kozlova IV, Akopyan AI, Reshchikova VS. Efficiency of combination therapy in patients with primary open-angle glaucoma. National journal glaucoma. 2011;(3):25-29. (In Russ.)
Petrov SY, Kozlova I V., Poleva RP. Conservative treatment for cataract: state-of-the-art. Russian Journal of Clinical Ophthalmology. 2019;19(4): 206-210. (In Russ.). https://doi.org/10.32364/2311-7729-2019-19-4-206-210
Tamaki Y, Nagahara M, Araie M, Tomita K, Sandoh S, Tomidokoro A. Topical latanoprost and optic nerve head and retinal circulation in humans. J Ocul Pharmacol Ther. 2001;17(5):403-411. https://doi.org/10.1089/108076801753266785
Makimoto Y, Sugiyama T, Kojima S, Azuma I. Long-term effect of topically applied isopropyl unoprostone on microcirculation in the human ocular fundus. Jpn J Ophthalmol. 2002;46(1):31-35.
Tamaki Y, Araie M, Tomita K, Nagahara M. Effect of topical betaxolol on tissue circulation in the human optic nerve head. J Ocul Pharmacol Ther. 1999;15(4):313-321. https://doi.org/10.1089/jop.1999.15.313
Tamaki Y, Araie M, Muta K. Effect of topical dorzolamide on tissue circulation in the rabbit optic nerve head. Jpn J Ophthalmol. 1999;43(5):386-391.
Ohguro I, Ohguro H. The effects of a fixed combination of 0.5% timolol and 1% dorzolamide on optic nerve head blood circulation. J Ocul Pharmacol Ther. 2012;28(4):392-396. https://doi.org/10.1089/jop.2011.0243
Acceoted 03.11.2025